Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYBN Cybin	$7.48 -2.1%	$7.64	$4.81 ▼ $13.88	$176.45M	0.68	323,584 shs	367,201 shs
GHRS GH Research	$13.50 -2.5%	$14.01	$6.00 ▼ $20.50	$720.07M	0.98	258,217 shs	84,476 shs
KALV KalVista Pharmaceuticals	$13.46 -0.4%	$13.50	$7.30 ▼ $16.32	$680.09M	0.05	656,497 shs	436,472 shs
KURA Kura Oncology	$7.90 -2.1%	$6.43	$5.41 ▼ $21.57	$700.45M	0.41	1.94 million shs	1.68 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYBN Cybin	-2.09%	+4.62%	+2.47%	-6.03%	+1,927.10%
GHRS GH Research	-2.46%	+3.21%	-3.43%	+12.69%	+22.73%
KALV KalVista Pharmaceuticals	-0.37%	+0.37%	-2.75%	+14.46%	+4.42%
KURA Kura Oncology	-2.11%	+3.27%	+25.40%	+39.08%	-60.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYBN Cybin	2.3145 of 5 stars	3.6	0.0	0.0	1.6	0.8	1.3
GHRS GH Research	2.2792 of 5 stars	3.4	3.0	0.0	1.7	2.5	0.0
KALV KalVista Pharmaceuticals	3.661 of 5 stars	3.6	1.0	4.4	2.0	0.8	0.6
KURA Kura Oncology	3.9398 of 5 stars	3.4	3.0	4.7	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYBN Cybin	3.25	Buy	$85.00	1,036.36% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	137.04% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	95.29% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.10	205.06% Upside

Current Analyst Ratings Breakdown

Latest CYBN, GHRS, KALV, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$28.00 ➝ $24.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
KURA Kura Oncology	$53.88M	12.73	N/A	N/A	$3.52 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.26	N/A	N/A	N/A	N/A	-52.32%	-29.59%	11/6/2025 (Estimated)

Latest CYBN, GHRS, KALV, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	-$0.75	-$0.90	-$0.75	$64.95 million	$15.29 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYBN Cybin	N/A	24.24	24.24
GHRS GH Research	N/A	29.49	29.49
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
KURA Kura Oncology	0.02	6.16	6.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYBN Cybin	17.94%
GHRS GH Research	56.90%
KALV KalVista Pharmaceuticals	N/A
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
CYBN Cybin	15.00%
GHRS GH Research	41.60%
KALV KalVista Pharmaceuticals	4.30%
KURA Kura Oncology	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
KALV KalVista Pharmaceuticals	100	50.34 million	48.18 million	Optionable
KURA Kura Oncology	130	86.80 million	81.24 million	Optionable

CYBN, GHRS, KALV, and KURA Headlines

Recent News About These Companies

AlphaQuest LLC Boosts Stock Holdings in Kura Oncology, Inc. $KURA

August 30 at 4:33 AM | marketbeat.com

Vanguard Group Inc. Buys 129,337 Shares of Kura Oncology, Inc. $KURA

August 30 at 3:09 AM | marketbeat.com

Kura Oncology to Participate in Three Upcoming Investor Conferences

August 28 at 7:30 AM | globenewswire.com

Kura Oncology, Inc. $KURA Shares Purchased by Russell Investments Group Ltd.

August 28 at 3:37 AM | marketbeat.com

Alethea Capital Management LLC Raises Holdings in Kura Oncology, Inc. $KURA

August 23, 2025 | marketbeat.com

Kura Oncology, Inc. $KURA Shares Bought by Algert Global LLC

August 20, 2025 | marketbeat.com

Wall Street Zen Upgrades Kura Oncology (NASDAQ:KURA) to "Hold"

August 18, 2025 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up - Here's Why

August 17, 2025 | marketbeat.com

Kura Oncology Inc. (KURA) Stock Price Today - WSJ

August 16, 2025 | wsj.com

Kura Oncology (NASDAQ:KURA) Trading Up 10.7% - What's Next?

August 14, 2025 | marketbeat.com

Kura Oncology’s Earnings Call: Progress Amidst Challenges

August 13, 2025 | msn.com

Kura Oncology (NASDAQ:KURA) Price Target Cut to $24.00 by Analysts at JMP Securities

August 12, 2025 | marketbeat.com

Wedbush Issues Negative Estimate for Kura Oncology Earnings

August 12, 2025 | marketbeat.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 12, 2025 | marketbeat.com

Kura Oncology price target lowered to $27 from $29 at BofA

August 11, 2025 | msn.com

Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates

August 10, 2025 | uk.finance.yahoo.com

Kura Oncology (NASDAQ:KURA) Cut to "Sell" at Wall Street Zen

August 10, 2025 | marketbeat.com

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Kura (KURA) Revenue Drops 61%

August 7, 2025 | fool.com

Kura Oncology Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYBN, GHRS, KALV, and KURA Company Descriptions

Cybin NYSE:CYBN

$7.48 -0.16 (-2.09%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.64 +0.16 (+2.21%)

As of 08/29/2025 07:58 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

GH Research NASDAQ:GHRS

$13.50 -0.34 (-2.46%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$13.41 -0.09 (-0.67%)

As of 08/29/2025 05:51 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

KalVista Pharmaceuticals NASDAQ:KALV

$13.46 -0.05 (-0.37%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$13.75 +0.29 (+2.15%)

As of 08/29/2025 05:07 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Kura Oncology NASDAQ:KURA

$7.90 -0.17 (-2.11%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.03 +0.13 (+1.59%)

As of 08/29/2025 07:50 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time